Brevan Howard Capital Management LP Has $4.43 Million Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Brevan Howard Capital Management LP lifted its position in Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 2,795.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 876,340 shares of the company's stock after buying an additional 846,070 shares during the period. Brevan Howard Capital Management LP owned approximately 0.70% of Humacyte worth $4,426,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Vontobel Holding Ltd. acquired a new position in Humacyte in the fourth quarter worth approximately $50,000. Petros Family Wealth LLC acquired a new position in shares of Humacyte in the 4th quarter worth $50,000. Syon Capital LLC acquired a new position in shares of Humacyte in the 4th quarter worth $54,000. Brookstone Capital Management acquired a new stake in shares of Humacyte during the fourth quarter worth $56,000. Finally, ACT Wealth Management LLC purchased a new stake in shares of Humacyte during the fourth quarter valued at $57,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Insider Buying and Selling at Humacyte

In other news, Director Kathleen Sebelius purchased 50,000 shares of Humacyte stock in a transaction dated Tuesday, April 8th. The stock was acquired at an average cost of $1.32 per share, for a total transaction of $66,000.00. Following the acquisition, the director now directly owns 91,207 shares in the company, valued at $120,393.24. This represents a 121.34 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Dale A. Sander purchased 20,000 shares of the company's stock in a transaction dated Thursday, April 10th. The shares were acquired at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the purchase, the chief financial officer now owns 40,600 shares in the company, valued at $62,118. The trade was a 97.09 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 83,993 shares of company stock worth $118,224 over the last 90 days. 11.20% of the stock is currently owned by corporate insiders.

Humacyte Stock Performance

Shares of HUMA stock traded down $0.02 during trading on Friday, hitting $1.19. 2,020,672 shares of the company were exchanged, compared to its average volume of 3,641,672. The business's 50-day simple moving average is $1.95 and its 200 day simple moving average is $3.62. Humacyte, Inc. has a twelve month low of $1.15 and a twelve month high of $9.97. The firm has a market capitalization of $184.59 million, a price-to-earnings ratio of -0.89 and a beta of 1.64.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its earnings results on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to analyst estimates of $0.64 million. On average, equities analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research note on Wednesday, March 26th. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Humacyte in a research report on Wednesday, March 12th. Finally, Benchmark restated a "buy" rating on shares of Humacyte in a research report on Thursday, February 27th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Humacyte currently has a consensus rating of "Buy" and an average target price of $13.71.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.